Try our beta test site
240 studies found for:    (lymphoma [CONDITION] OR CLL) [CONDITION] AND rituxan [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT
Condition: Mantle-cell Lymphoma
Intervention: Drug: subcutaneous Rituximab
2 Recruiting Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
3 Recruiting Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Condition: Lymphoma
Interventions: Drug: Rituximab;   Drug: Pembrolizumab
4 Not yet recruiting A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Condition: Lymphoma, Follicular
Interventions: Biological: SAIT101;   Biological: MabThera®
5 Recruiting Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II
Condition: Lymphoma
Interventions: Drug: Rituximab;   Radiation: Radiation
6 Recruiting Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
7 Recruiting Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide
8 Recruiting Combination of Rituximab and NK Immunotherapy for B Lymphoma
Condition: B-cell Lymphoma Recurrent
Interventions: Drug: Rituximab;   Biological: NK immunotherapy
9 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
10 Recruiting To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Biological: CT-P10;   Biological: Rituxan
11 Recruiting Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Condition: Marginal Zone B-cell Lymphoma
Intervention: Drug: bendamustine plus rituximab
12 Recruiting Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
Condition: Follicular Lymphoma
Interventions: Drug: Rituximab IV;   Drug: Rituximab SC
13 Recruiting A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Condition: Follicular Lymphoma
Interventions: Biological: PF-05280586;   Biological: MabThera®
14 Not yet recruiting Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Conditions: B Cell Lymphoma;   Lymphoma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Rituximab
15 Recruiting A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Condition: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Interventions: Drug: Imprime PGG;   Drug: Rituximab
16 Recruiting Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Rituximab
17 Recruiting Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Condition: Lymphoma
Intervention: Drug: Brentuximab vedotin & Rituximab
18 Recruiting Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Placebo
19 Recruiting An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: AZD 2014;   Drug: Rituximab
20 Recruiting A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Condition: Relapsed or Refractory Diffuse Large B Cell Lymphoma
Intervention: Drug: 131I-rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.